ACTG A5201 ATAZANAVIR/RITONAVIR AFTER SUSTAINED VIROLOGIC SUPPRESSION

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的主要目的是评估单独使用利托那韦强化的阿扎那韦(ATV/RTV)维持疗法24周后受试者病毒学失败的风险。病毒学失败被定义为连续两次血浆HIV-1RNA检测&200拷贝/毫升。HIV-1RNA检测结果为200拷贝/毫升的受试者必须在30天内返回，以确认病毒学失败，届时如果第二个病毒载量为1000拷贝/毫升，将进行实时基因分型。关于未来抗逆转录病毒治疗的决定将根据目前的临床指导方针做出，并可能包括恢复以前的联合治疗。所有在步骤2中永久停止研究治疗的受试者，包括那些因病毒学失败而改变治疗的受试者，将在研究中停止治疗。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The primary purpose of this study is to evaluate the risk of virologic failure in subjects 24 weeks after treatment with ritonavir-boosted atazanavir (ATV/RTV) maintenance therapy alone. Virologic failure is defined as 2 consecutive plasma HIV-1 RNA measurements >200 copies/mL. Subjects with HIV-1 RNA measurements >200 copies mL must return within 30 days for confirmation of virologic failure, at which point real-time genotyping will be performed if the second viral load is >1000 copies/mL. Decisions about future antiretroviral therapy will be made according to current clinical guidelines and may include resumption of previous combination therapy. All subjects who permanently discontinue study treatment on Step 2, including those who change therapy due to virologic failure, will be followed off treatment on study.